Soraprazan (remofuscin), a potassium-competitive acid blocker (P-CAB; formerly called an acid pump antagonist [APA]), is being developed by Katairo GmbH for the treatment of Stargardt's disease and dry age-related macular degeneration (AMD). Clinical development is underway for Stargardt's disease and dry age-related macular degeneration in the Netherlands and Germany. On 13 November 2013, orphan designation was granted by the European Commission to Katairo GmbH, Germany, for soraprazan for the treatment of Stargardt’s disease. Soraprazan is a a highly potent reversible, and fast-acting inhibitor of gastric H,K-ATPase. Soraprazan shows immediate inhibition of acid secretion in various in vitro models and in vivo and was found to be more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases.

Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.

Suronacrine (also known as HP128) is a tetrahydroacridinol derivative patented by Hoechst-Roussel Pharmaceuticals, Inc for the treatment of various memory dysfunctions characterized by decreased cholinergic function. The activity ofHP128 is attributable to its inhibition of both norepinephrine uptake and cholinesterase enzyme activity. Suronacrine has enhanced memory in animals with combined cholinergic and adrenergic lesions. In preclinical models, Suronacrine blocks responses to nerve stimulation and to carbachol, but increased responses to acetylcholine. Extracellular recording of nerve terminal currents from triangularis sterni preparations revealed that Suronacrine had a selective blocking action on the waveform associated with K+ currents.

Tixadil is a coronary vasodilator and sedative agent.

Taselisib (GDC-0032) is an highly selective small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) p110-α isoform (PIK3CA). Taselisib is designed to bind to the ATP-binding pocket of PIK3CA to potentially prevent subsequent downstream signaling. Taselisib caused a strong differential growth inhibition in carcinoma cells harbored oncogenic PIK3CA mutations. In preclinical studies, taselisib induced growth inhibition in PIK3CA-mutant xenograft mouse models. Genentech (a Roche subsidiary) is developing taselib primarily for the treatment of solid tumours.

IPROPLATIN is a quadrivalent second-generation platinum complex. It binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and tumor cell death. IPROPLATIN was discontinued in phase III clinical trials.